Drug Details
| General Information of the Drug (ID: DR2430) | ||||
|---|---|---|---|---|
| Name |
Deoxynivalenol
|
|||
| Synonyms |
DEOXYNIVALENOL; 51481-10-8; Vomitoxin; Dehydronivalenol; 4-Deoxynivalenol; 4-Desoxynivalenol; Desoxynivalenol; UNII-JT37HYP23V; Rd toxin; JT37HYP23V; 3alpha,7alpha,15-Trihydroxy-12,13-epoxytrichothec-9-en-8-one; 3?,7?,15-Trihydroxy-12,13-epoxytrichothec-9-en-8-one; (3beta,7alpha)-3,7,15-Trihydroxy-12,13-Epoxytrichothec-9-En-8-One; Trichothec-9-en-8-one, 12,13-epoxy-3,7,15-trihydroxy-, (3a,7a)-; NSC 269144; CCRIS 7801; (3alpha,7alpha)-3,7,15-trihydroxy-12,13-epoxytrichothec-9-en-8-one; Deoxynivalenol 100 microg/mL in Acetonitrile; HSDB 7245; 12,13-Epoxy-3-alpha,7-alpha,15-trihydroxy-9-trichothecen-8-one; CHEMBL513300; SCHEMBL2694361; DTXSID3020382; CHEBI:10022; Deoxynivalenol, reference material; HY-N6684; ZINC5457778; CD0228; MFCD09039270; AKOS024457908; CS-W012154; Trichothec-9-en-8-one, 12,13-epoxy-3,7,15-trihydroxy-, (3-alpha,7-alpha)-; B7557; Q420518; (3beta,7alpha,12R)-3,7,15-trihydroxy-12,13-epoxytrichothec-9-en-8-one; 4-Deoxynivalenol in acetonitrile, IRMM(R) certified Reference Material; Deoxynivalenol solution, 100 mug/mL in acetonitrile, analytical standard; Deoxynivalenol solution, 200 mug/mL in ethyl acetate: methanol (95:5), analytical standard; 3J6; Deoxynivalenol solution, certified reference material, 200 mug/mL in ethyl acetate: methanol (95:5), ampule of 1 mL
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Lung cancer [ICD-11: 2C25] | Investigative | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C15H20O6
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CC1=CC2C(C(C1=O)O)(C3(CC(C(C34CO4)O2)O)C)CO
|
|||
| InChI |
1S/C15H20O6/c1-7-3-9-14(5-16,11(19)10(7)18)13(2)4-8(17)12(21-9)15(13)6-20-15/h3,8-9,11-12,16-17,19H,4-6H2,1-2H3/t8-,9-,11-,12-,13-,14-,15+/m1/s1
|
|||
| InChIKey |
LINOMUASTDIRTM-QGRHZQQGSA-N
|
|||
| CAS Number |
CAS 51481-10-8
|
|||
| ChEBI ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug | ||||||
| Schisandrin A | Schisandra chinensis | Click to Show/Hide the Molecular Data of This NP | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Sch A decreased the DON-induced cyclooxygenase-2 expression and prostaglandin E2 production and pro-inflammatory cytokine interleukin 8 expression and secretion. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Proto-oncogene c-Myc (MYC) | Molecule Info | [3] | |
| KEGG Pathway | MAPK signaling pathway | Click to Show/Hide | ||
| 2 | ErbB signaling pathway | |||
| 3 | Cell cycle | |||
| 4 | PI3K-Akt signaling pathway | |||
| 5 | Wnt signaling pathway | |||
| 6 | TGF-beta signaling pathway | |||
| 7 | Hippo signaling pathway | |||
| 8 | Signaling pathways regulating pluripotency of stem cells | |||
| 9 | Jak-STAT signaling pathway | |||
| 10 | Thyroid hormone signaling pathway | |||
| 11 | Hepatitis B | |||
| 12 | HTLV-I infection | |||
| 13 | Epstein-Barr virus infection | |||
| 14 | Pathways in cancer | |||
| 15 | Transcriptional misregulation in cancer | |||
| 16 | Proteoglycans in cancer | |||
| 17 | MicroRNAs in cancer | |||
| 18 | Colorectal cancer | |||
| 19 | Endometrial cancer | |||
| 20 | Thyroid cancer | |||
| 21 | Bladder cancer | |||
| 22 | Chronic myeloid leukemia | |||
| 23 | Acute myeloid leukemia | |||
| 24 | Small cell lung cancer | |||
| 25 | Central carbon metabolism in cancer | |||
| NetPath Pathway | IL9 Signaling Pathway | Click to Show/Hide | ||
| 2 | TCR Signaling Pathway | |||
| 3 | IL2 Signaling Pathway | |||
| 4 | IL4 Signaling Pathway | |||
| 5 | EGFR1 Signaling Pathway | |||
| 6 | TGF_beta_Receptor Signaling Pathway | |||
| 7 | Notch Signaling Pathway | |||
| 8 | Wnt Signaling Pathway | |||
| 9 | TSH Signaling Pathway | |||
| Panther Pathway | Interleukin signaling pathway | Click to Show/Hide | ||
| 2 | Oxidative stress response | |||
| 3 | PDGF signaling pathway | |||
| 4 | Wnt signaling pathway | |||
| 5 | p53 pathway feedback loops 2 | |||
| 6 | CCKR signaling map ST | |||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | Click to Show/Hide | ||
| 2 | Notch signaling pathway | |||
| 3 | p73 transcription factor network | |||
| 4 | E2F transcription factor network | |||
| 5 | CD40/CD40L signaling | |||
| 6 | Validated targets of C-MYC transcriptional activation | |||
| 7 | Presenilin action in Notch and Wnt signaling | |||
| 8 | LKB1 signaling events | |||
| 9 | Regulation of Telomerase | |||
| 10 | IL2-mediated signaling events | |||
| 11 | C-MYC pathway | |||
| 12 | IL2 signaling events mediated by PI3K | |||
| 13 | Ceramide signaling pathway | |||
| 14 | AP-1 transcription factor network | |||
| 15 | FOXM1 transcription factor network | |||
| 16 | IL6-mediated signaling events | |||
| 17 | PDGFR-beta signaling pathway | |||
| 18 | C-MYB transcription factor network | |||
| 19 | Validated nuclear estrogen receptor alpha network | |||
| 20 | Regulation of nuclear beta catenin signaling and target gene transcription | |||
| 21 | IL2 signaling events mediated by STAT5 | |||
| 22 | Validated targets of C-MYC transcriptional repression | |||
| Reactome | NOTCH1 Intracellular Domain Regulates Transcription | Click to Show/Hide | ||
| 2 | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | |||
| 3 | Constitutive Signaling by NOTCH1 PEST Domain Mutants | |||
| 4 | Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | |||
| 5 | Binding of TCF/LEF:CTNNB1 to target gene promoters | |||
| 6 | MAPK6/MAPK4 signaling | |||
| 7 | Cyclin E associated events during G1/S transition | |||
| 8 | Cyclin A:Cdk2-associated events at S phase entry | |||
| WikiPathways | DNA Damage Response (only ATM dependent) | Click to Show/Hide | ||
| 2 | DNA Damage Response | |||
| 3 | ErbB Signaling Pathway | |||
| 4 | Notch Signaling Pathway | |||
| 5 | IL-2 Signaling Pathway | |||
| 6 | G1 to S cell cycle control | |||
| 7 | Wnt Signaling Pathway | |||
| 8 | p38 MAPK Signaling Pathway | |||
| 9 | Wnt Signaling Pathway and Pluripotency | |||
| 10 | MAPK Signaling Pathway | |||
| 11 | TGF beta Signaling Pathway | |||
| 12 | Wnt Signaling Pathway Netpath | |||
| 13 | PPAR Alpha Pathway | |||
| 14 | Ectoderm Differentiation | |||
| 15 | Hair Follicle Development: Organogenesis (Part 2 of 3) | |||
| 16 | Bladder Cancer | |||
| 17 | Mammary gland development pathway - Involution (Stage 4 of 4) | |||
| 18 | Hair Follicle Development: Induction (Part 1 of 3) | |||
| 19 | S Phase | |||
| 20 | Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | |||
| 21 | Signaling by NOTCH1 | |||
| 22 | Structural Pathway of Interleukin 1 (IL-1) | |||
| 23 | Aryl Hydrocarbon Receptor | |||
| 24 | Polycystic Kidney Disease Pathway | |||
| 25 | Apoptosis | |||
| 26 | Retinoblastoma (RB) in Cancer | |||
| 27 | Spinal Cord Injury | |||
| 28 | Integrated Pancreatic Cancer Pathway | |||
| 29 | Gastric cancer network 2 | |||
| 30 | B Cell Receptor Signaling Pathway | |||
| 31 | Prostate Cancer | |||
| 32 | Metastatic brain tumor | |||
| 33 | TSLP Signaling Pathway | |||
| 34 | Neural Crest Differentiation | |||
| 35 | IL-7 Signaling Pathway | |||
| 36 | TSH signaling pathway | |||
| 37 | Integrated Breast Cancer Pathway | |||
| 38 | Integrated Cancer pathway | |||
| 39 | Mitotic G1-G1/S phases | |||
| 40 | TP53 Network | |||
| 41 | miRNAs involved in DNA damage response | |||
| 42 | miRNA Regulation of DNA Damage Response | |||
| 43 | IL-5 Signaling Pathway | |||
